Scarica l'app Stockscreener
14.69
0.89%
0.13
Pre-mercato:
14.54
-0.15
-1.02%
Precedente Chiudi:
$14.56
Aprire:
$14.62
Volume 24 ore:
802.81K
Relative Volume:
0.78
Capitalizzazione di mercato:
$1.05B
Reddito:
$114.04M
Utile/perdita netta:
$-330.15M
Rapporto P/E:
-3.1057
EPS:
-4.73
Flusso di cassa netto:
$-274.85M
1 W Prestazione:
-1.41%
1M Prestazione:
+0.89%
6M Prestazione:
+38.06%
1 anno Prestazione:
+86.19%
Intervallo 1D:
$14.24
$14.85
Intervallo di 1 settimana:
$14.12
$16.45
Portata 52W:
$2.21
$16.45
Phathom Pharmaceuticals Inc Stock (PHAT) Company Profile
Nome
Phathom Pharmaceuticals Inc
Settore
Industria
Telefono
(877) 742-8466
Indirizzo
100 CAMPUS DRIVE,, FLORHAM PARK, NJ
Confronta PHAT con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PHAT
Phathom Pharmaceuticals Inc
|
14.69 | 1.04B | 114.04M | -330.15M | -274.85M | -4.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.71 | 114.69B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
752.62 | 77.91B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
850.95 | 54.05B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
391.50 | 52.52B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
196.92 | 42.02B | 447.02M | -1.18B | -906.14M | -6.1812 |
Phathom Pharmaceuticals Inc Stock (PHAT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-12 | Iniziato | Raymond James | Strong Buy |
| 2025-12-09 | Iniziato | Barclays | Equal Weight |
| 2025-02-14 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-05-03 | Iniziato | Stifel | Buy |
| 2024-01-05 | Reiterato | Needham | Buy |
| 2023-08-09 | Iniziato | H.C. Wainwright | Buy |
| 2023-05-11 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2023-03-13 | Iniziato | Craig Hallum | Buy |
| 2022-10-21 | Iniziato | Jefferies | Buy |
| 2022-05-06 | Downgrade | Evercore ISI | Outperform → In-line |
| 2021-05-12 | Aggiornamento | Goldman | Sell → Neutral |
| 2021-02-17 | Iniziato | BMO Capital Markets | Outperform |
| 2021-02-02 | Iniziato | Guggenheim | Buy |
| 2020-06-26 | Downgrade | Goldman | Neutral → Sell |
| 2019-11-20 | Iniziato | Evercore ISI | Outperform |
| 2019-11-19 | Iniziato | Goldman | Neutral |
| 2019-11-19 | Iniziato | Jefferies | Buy |
| 2019-11-19 | Iniziato | Needham | Buy |
Mostra tutto
Phathom Pharmaceuticals Inc Borsa (PHAT) Ultime notizie
Phathom Pharmaceuticals Inc Stock Analysis and ForecastEarnings Miss Alerts & Affordable Portfolio Tips - earlytimes.in
Raymond James Financial Begins Coverage on Phathom Pharmaceuticals (NASDAQ:PHAT) - MarketBeat
Frazier Life Sciences Management L.P. Purchases 2,357,210 Shares of Phathom Pharmaceuticals, Inc. $PHAT - MarketBeat
Phathom Pharmaceuticals (NASDAQ:PHAT) Reaches New 12-Month HighWhat's Next? - MarketBeat
683 Capital Management LLC Grows Stock Position in Phathom Pharmaceuticals, Inc. $PHAT - MarketBeat
Phathom Pharmaceuticals stock hits 52-week high at $16.27 By Investing.com - Investing.com India
Raymond James initiates Phathom Pharmaceuticals stock with Strong Buy rating - Investing.com Canada
Phathom Pharmaceuticals (NASDAQ:PHAT) Upgraded at Barclays - MarketBeat
(PHAT) and the Role of Price-Sensitive Allocations - news.stocktradersdaily.com
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Barclays Initiates Coverage of Phathom Pharmaceuticals (PHAT) with Equal-Weight Recommendation - Nasdaq
Barclays Initiates Phathom Pharmaceuticals at Equalweight With $16 Price Target - marketscreener.com
Is WPIL Limited Still a Good Stock to Buy After Recent Earnings - earlytimes.in
Responsive Playbooks and the PHAT Inflection - news.stocktradersdaily.com
Phathom Pharmaceuticals (NASDAQ:PHAT) Sets New 1-Year HighWhat's Next? - MarketBeat
Phathom Pharmaceuticals stock hits 52-week high at 16.08 USD By Investing.com - Investing.com Nigeria
Phathom Pharmaceuticals stock hits 52-week high at 16.08 USD - Investing.com
Is Phathom Pharmaceuticals Inc a good long term investmentIPO Market Watch & Budget Friendly Capital Growth - earlytimes.in
How Phathom Pharmaceuticals Inc. stock benefits from strong dollarJuly 2025 Earnings & Accurate Intraday Trading Signals - moha.gov.vn
Phathom Pharmaceuticals research links GLP-1 use to higher GERD risk - Traders Union
Phathom Pharmaceuticals Inc. (PHAT) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Phathom Pharmaceuticals: Superior Efficacy Drives Vonoprazan Growth (NASDAQ:PHAT) - Seeking Alpha
What Wall Street predicts for Phathom Pharmaceuticals Inc. stock priceJuly 2025 Macro Moves & Safe Entry Momentum Tips - newser.com
Is Phathom Pharmaceuticals Inc. stock a contrarian buyGap Up & Daily Growth Stock Tips - newser.com
Is Phathom Pharmaceuticals Inc. stock a smart buy before Fed meeting2025 Market Overview & Fast Moving Stock Trade Plans - newser.com
What margin trends mean for Phathom Pharmaceuticals Inc. stockJuly 2025 Summary & Daily Stock Momentum Reports - newser.com
Is Phathom Pharmaceuticals Inc. stock positioned for digital transformation2025 Market Sentiment & Safe Entry Trade Reports - newser.com
Understanding the Setup: (PHAT) and Scalable Risk - news.stocktradersdaily.com
Comparing Phathom Pharmaceuticals Inc. in custom built stock radarsJuly 2025 Momentum & AI Powered Buy and Sell Recommendations - newser.com
Volume spikes in Phathom Pharmaceuticals Inc. stock – what they meanMarket Risk Analysis & Growth Oriented Trade Recommendations - newser.com
Will Phathom Pharmaceuticals Inc. stock reach all time highs in 20252025 Top Decliners & Proven Capital Preservation Methods - newser.com
Volatility clustering patterns for Phathom Pharmaceuticals Inc.July 2025 Review & Capital Efficiency Focused Strategies - newser.com
Phathom Pharmaceuticals Inc Azioni (PHAT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.36%
1.05%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):